A Phase 1 Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors
Latest Information Update: 09 May 2024
At a glance
- Drugs MOR 210 (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- Sponsors I-MAB Biopharma
- 09 Dec 2022 Status changed from active, no longer recruiting to completed.
- 31 Aug 2022 According to an I-MAB Biopharma media release, patient recruitment for dose escalation will complete in Q3 2022. Clinical study report of this phase 1 study is expected in Q4 2022.
- 12 Jul 2022 Planned End Date changed from 30 Mar 2022 to 16 Feb 2023.